DeepCure Presents 'HyperCure' Clinical Trial Status at Australian and New Zealand Urological Association Meeting

DeepQure announced on the 4th that Changwook Jung, co-founder and professor of urology at Seoul National University Hospital, presented the clinical results of HyperQure at the annual conference of the Urological Society of Australia and New Zealand (USANZ) held on the 1st (local time).

Jangwook Jeong, co-founder of DeepCure and professor of urology at Seoul National University Hospital, is presenting at USANZ. Provided by DeepCure

USANZ is one of the globally recognized academic conferences in the field of urology. It plays an important role in providing the latest information to medical professionals and supporting clinical research. In particular, it offers a platform for new technology and drug development, providing global medical device and biotech companies with opportunities to introduce innovative treatments.

Professor Changwook Jung presented the current status and results of HyperQure's clinical trials ongoing in Korea and the United States under the theme "When urologists meet hypertension." HyperQure is an innovative extravascular renal denervation (RDN) device for hypertension treatment, proposing a differentiated approach from the conventional intravascular catheter method (Intravascular RDN).

In this presentation, the superiority and safety of HyperQure's extravascular renal denervation approach, which overcomes the limitations of the conventional intravascular catheter method, were shared with the attendees. There was an encouraging atmosphere among the participants regarding HyperQure's superior clinical results compared to existing methods and the significant contribution urologists can make to hypertension treatment.

A DeepQure representative said, "We are very pleased to present the clinical results of HyperQure at the international academic conference USANZ," adding, "Through this presentation, HyperQure has gained international attention and has been recognized as an important study among urology experts."

Meanwhile, DeepQure is a medtech company researching and developing an innovative medical device for hypertension treatment through the premarket approval (PMA) process, the first in Korea to obtain approval from the U.S. Food and Drug Administration (FDA). Clinical trials are currently underway in Korea and the United States targeting patients with resistant hypertension.